USA flag logo/image

An Official Website of the United States Government

Development, Production and Evaluation of a Multivalent Adenoviral Plague…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88686
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI071634
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NORWELL, INC.
415 JACKSON HILL ST HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Development, Production and Evaluation of a Multivalent Adenoviral Plague Vaccine
Agency: HHS
Contract: 1R43AI071634-01A2
Award Amount: $531,752.00
 

Abstract:

DESCRIPTION (provided by applicant): The final objective of this effort is to construct and test a multivalent adenoviral vaccine candidate that elicits a potent immune response against Yersinia pestis, the causative agent of plague. The proposed work is a collaborative effort between the University of Texas Medical Branch (UTMB), Norwell, Inc., and Introgen Therapeutics, Inc. The plague vaccine project was selected in response to the growing concern surrounding the organism's use in a potential terrorism e vent. The NIAID, in response to this threat, has classified the organism as a Class A priority organism. Currently there are no commercially available vaccines for protection from plague in the instance of a bioterrorism event. The lack of a vaccine is par ticularly worrisome because of the pathogen's capability to inflict widespread morbidity and mortality, upon exposure, to both civilians and military personnel. Project Aims will focus on the development, production and evaluation of a vaccine candidate fe aturing the low calcium response (LcrV) antigen alone or in combination with two other protective Yersinia pestis antigens Caf1 (F1 capsular antigen) and YscF (a type 3 secretion system structural protein) in an adenoviral vector system. The adenoviral vec tor system was selected because it not only provides a viable delivery vehicle, but also because of the ability of the vector to elicit an immune response. Both mouse and guinea pig animal models proposed in this study are currently being used at the UTMB for inhalational anthrax and plague, and the aerobiology unit for infecting animals by the aerosol route is in place. We believe this program will provide a valuable first line of defense by deterrence for potential terrorists in search of weapons where no vaccine or treatment option exists. Further, the development of a multivalent adenoviral vaccine is not only significant for biodefense but also for combating global infectious disease. PUBLIC HEALTH RELEVANCE: The objective of this project is to construc t and test a multivalent adenoviral vaccine candidate against Yersinia pestis (plague), a Class A priority organism. Currently there is no licensed vaccine for human use to protect against infection with plague despite the pathogen's capability to inflict widespread morbidity and mortality upon exposure to both civilians and military personnel.

Principal Investigator:

Business Contact:


ericrothe@msn.com
Small Business Information at Submission:

NORWELL, INC.
NORWELL, INC. 415 JACKSON HILL ST HOUSTON, TX 77007

EIN/Tax ID: 145971385
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No